Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information, see Section 1.

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Why South Carolina safety Nick Emmanwori was not selected during the first round of the NFL draft. The first round of the 2025 NFL draft took place on Thursday ...

After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG–trastuzumab and trastuzumab, but the absolute bioavailability of PEG–trastuzumab was 100% ...

At 7-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab alone.

A sample size of 22 patients was estimated to provide 90.7% power with two-sided alpha 0.05 to detect a difference of 70 minutes in the primary end point by treatment arm (IV v SC). Results ...

Patients with early breast cancer when trastuzumab was given as neoadjuvant therapy (RR, 1.30; 95% CI, 0.47-3.59; with consistency across studies, I2 = 0%; P =.57).

Reference Jackisch C, Im S, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...